search index hum-molgen

 

HUM-MOLGEN events
PHARMACOGENOMICS EUROPE
 
Cambridge Healthtech Institute , Amsterdam, The Netherlands
May 17-18, 2000

As synergies between molecular pharmacology and toxicology, genetic variation, SNP identification and scoring, population genetics, and stratification for clinical trials develop further, the “discipline” of pharmacogenomics is coming into its own. Pharmacogenomics is increasingly being integrated into the entire drug discovery and development process, from target selection and validation to lead identification and optimization to preclinical analysis up through the end of phase III and beyond approval. This is being made possible by both higher throughput genotyping and advances in gene functional analysis, without which pharmacogenomics would be too costly to apply on a wide-scale commercial basis. This conference will emphasize the future of pharmacogenomics beyond individualization of patient treatment and trial stratification while highlighting its value for drug discovery and development. This includes discussion and prediction of where the field will be two years (and more) from now.

Organized by:

Cambridge Healthtech Institute

Deadline for Abstracts:

April 7, 2000

Registration:

Available on-line
Email for Requests and Registration: jlaakso@healthtech.com
 
 

Posted by: Jennifer Laakso   Host: 140.239.39.137
date: January 19, 2000 17:49:02
Generated by meetings and positions 2.0 by Kai Garlipp
Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany.
4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.